CervoMed (CRVO) Corporate presentation summary

Strategic focus and pipeline

• Developing neflamapimod, an oral small molecule targeting neuroinflammation and neurodegeneration in age-related brain disorders.

• Pipeline includes programs in dementia with Lewy bodies (DLB), non-fluent variant primary progressive aphasia (nfvPPA), and recovery after ischemic stroke (RAS).

• Neflamapimod has received FDA Fast Track and Orphan Drug designations for DLB and nfvPPA, respectively.

• Multiple clinical milestones anticipated in the next 12–18 months, including Phase 3 initiation in DLB and Phase 2a data for nfvPPA and RAS.

• Worldwide commercial rights retained across programs.

Scientific rationale and clinical need

• Basal forebrain cholinergic neuron degeneration is central to multiple neurological disorders and is a validated therapeutic target.

• DLB is characterized by rapid progression, high unmet need, and significant impact on quality of life and caregiver burden.

• DLB without Alzheimer’s co-pathology (~50% of DLB cases) offers a focused drug development opportunity with potentially faster regulatory approval.

• No approved therapies currently target the underlying disease process in DLB in the US or EU.

Neflamapimod mechanism and preclinical/clinical data

• Neflamapimod selectively inhibits p38a, reversing synaptic dysfunction and neurodegeneration in the basal forebrain.

• Preclinical studies showed reversal of cholinergic neuron loss and improved behavioral outcomes in animal models.

• Phase 2a trial in DLB demonstrated significant improvements in dementia severity and gait, especially in patients without AD co-pathology.